Hepatitis C treatment in a district Hospital

Espírito Santo, Margarida; Guerreiro, Luisa; Nascimento, Tânia

Publication

Hepatitis C treatment in a district Hospital

2015-10Conference object

dc.contributor.author	Espírito Santo, Margarida
dc.contributor.author	Guerreiro, Luisa
dc.contributor.author	Nascimento, Tânia
dc.date.accessioned	2019-01-23T11:07:09Z
dc.date.available	2019-01-23T11:07:09Z
dc.date.issued	2015-10
dc.description	Publicação sob a forma de Poster	pt_PT
dc.description.abstract	The aim of this study was the characterization of patients with Hepatitis C (HCV) under treatment. Patients included in this study were followed in a Portuguese District Hospital between January 2012 and September 2014, have received treatment for HCV and who had at least one infectiology consultation in this period. Data were collected from the hospital computer system, and patient´s data were collected anonymously, without patient identification. Data analysis was performed using SPSS v22.0. Were included in this study 87 patients who met the inclusion criteria, 75% (n=65) were males and 25% (n=22) female, with a mean age of 45±10 years. Most patients included in this study were Portuguese, resident in the Hospital district and nearby districts. Patients were diagnosed with HCV with a mean age of 3311 years, were followed on average for 53.5 years in this Hospital, and were diagnosed with HCV on average 126.9 years ago. Among these patients, 44% (n=38) had genotype 1, 2% (n=2) genotype 2, 17% (n=15) genotype 3, 13% (n=11) genotype 4 and 24% (n=21) with unknown genotype. Most frequent treatment regimens used by patients included in the study were the association of pegylated interferon alfa 2b (100mcg/week) and ribavirin (1000 mg/day) (52%; n=45); pegylated interferon alpha 2a (180mcg/week) and ribavirin (1000 mg/day) (42%; n=36). Other associations were used but less frequently: pegylated interferon alfa 2a + ribavirin + boceprevir (2%; n=2); pegylated interferon alfa 2b + ribavirin + boceprevir (3%; n=3); and pegylated interferon alfa 2a + ribavirin + telaprevir (1%; n=1). Among included patients, 55 (63%) have performed, to date, one treatment for HCV, 19 (22%) have performed two treatments for HCV (using two different regimens or by using the same regimen twice), 9 (10%) already underwent treatment three times, 3 (3%) already underwent treatment four times and only one patient (1%) has conducted five treatments for HCV. Excluding patients who were receiving treatment at the time of data collection (September 2014), the average length of all other treatments performed by the patients was 82 months, and most (40%; n=51) of treatments performed by patients had a duration from 6 to 9 months. From the results, the standard treatment for patients with HCV appears to be in accordance with the existing guidelines for the treatment of this pathology. In the future it would be advisable further analysis and extended to other hospitals to assess the degree of compliance with currently existing national guidelines for the treatment of this pathology.	pt_PT
dc.description.version	info:eu-repo/semantics/publishedVersion	pt_PT
dc.identifier.uri	http://hdl.handle.net/10400.1/12302
dc.language.iso	eng	pt_PT
dc.peerreviewed	yes	pt_PT
dc.publisher	Ordem dos Farmacêuticos	pt_PT
dc.subject	Hepatitis C	pt_PT
dc.subject	Treatment	pt_PT
dc.title	Hepatitis C treatment in a district Hospital	pt_PT
dc.type	conference object
dspace.entity.type	Publication
oaire.citation.conferencePlace	Centro de Congressos de Lisboa	pt_PT
oaire.citation.title	Congresso Nacional dos Farmacêuticos	pt_PT
person.familyName	Neto Espírito-Santo
person.familyName	Nascimento
person.givenName	Margarida de Fátima
person.givenName	Tânia
person.identifier	2191220
person.identifier.ciencia-id	6215-22B3-56BF
person.identifier.ciencia-id	8F1D-1FFE-9777
person.identifier.orcid	0000-0002-2200-0015
person.identifier.orcid	0000-0003-2429-7374
person.identifier.scopus-author-id	57150665300
rcaap.rights	openAccess	pt_PT
rcaap.type	conferenceObject	pt_PT
relation.isAuthorOfPublication	34f3dbba-01c4-4cb3-b3a9-f6d05fac2753
relation.isAuthorOfPublication	f975caa2-7c09-4dca-ab01-23d4dcc587a2
relation.isAuthorOfPublication.latestForDiscovery	34f3dbba-01c4-4cb3-b3a9-f6d05fac2753